News

Avadel says court denies Jazz Pharma request on lumryz in narcolepsy (update)
"Avadel is pleased with the Court’s decision allowing the commercial launch of LUMRYZ in narcolepsy to proceed ... for the ...
Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience
Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate ...
Onlymyhealth26d
Does Idiopathic Hypersomnia Ever Go Away? Find Out From The Expert
If so, it might not just be regular fatigue, it could be Idiopathic Hypersomnia (IH). This neurological sleep disorder causes overwhelming daytime drowsiness, making it difficult to stay awake and ...
Dr. Sud Agarwal Leads iNGENu CRO in Launching Groundbreaking Clinical Trials for Sleep Disorders Following Ethics Approval
Melbourne, Australia, April 16, 2025 (GLOBE NEWSWIRE) -- iNGENū CRO, a specialist Contract Research Organization with deep expertise in the ...
Yahoo Finance23d
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Secondary endpoints include change in Idiopathic Hypersomnia Severity Scale (IHSS ... the safety and efficacy of ALKS 2680 in adults with narcolepsy type 1 (NCT06358950) and narcolepsy type ...
Finanznachrichten3mon
Alkermes plc: Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...